VRDN
Viridian Therapeutics (VRDN) Stock Valuation
Review Viridian Therapeutics (VRDN) valuation with company data, supporting context and links to related investor research.
Research record updated: . Individual measures may refer to different reporting periods.
- Price to book
- 4.11
- BTI fair market cap
- $1.42B
- Premium or discount
- 44.92%
- Market cap
- $2.06B
Viridian Therapeutics (VRDN) Stock Valuation research
The Viridian Therapeutics valuation page presents the available multiples, profitability measures and BTI fair-value context for VRDN. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.
BTI fair value is a model estimate, not a quoted market price. The underlying assumptions and valuation date must be checked in the valuation tool before using the premium or discount. A missing multiple must not be interpreted as zero cost or zero risk.